Immuneering annual stock-based compensation
2020
2021
2022
2023
2024
2025
Immuneering Stock-Based Compensation Growth & History (IMRX)
Immuneering's stock-based compensation was $6.3M for fiscal 2025.
View full Immuneering company overviewImmuneering annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.3M | −$190,231 | −2.93% |
| 2024 | 2024-12-31 | $6.5M | $774,231 | +13.52% |
| 2023 | 2023-12-31 | $5.7M | $1.7M | +40.91% |
| 2022 | 2022-12-31 | $4.1M | $2.3M | +125.47% |
| 2021 | 2021-12-31 | $1.8M | $715,854 | +65.87% |
| 2020 | 2020-12-31 | $1.1M | — | — |
Immuneering quarterly stock-based compensation
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.6M | $102,966 | +6.75% |
| Q1 2026 | 2026-03-31 | $1.6M | −$55,592 | −3.29% |
| Q4 2025 | 2025-12-31 | $1.6M | −$86,898 | −5.04% |
| Q3 2025 | 2025-09-30 | $1.5M | −$184,036 | −11.22% |
| Q2 2025 | 2025-06-30 | $1.5M | −$136,806 | −8.23% |
| Q1 2025 | 2025-03-31 | $1.7M | $217,509 | +14.75% |
| Q4 2024 | 2024-12-31 | $1.7M | $84,155 | +5.13% |
| Q3 2024 | 2024-09-30 | $1.6M | $160,956 | +10.88% |
| Q2 2024 | 2024-06-30 | $1.7M | $327,867 | +24.58% |
| Q1 2024 | 2024-03-31 | $1.5M | $201,253 | +15.80% |
| Q4 2023 | 2023-12-31 | $1.6M | $592,425 | +56.52% |
| Q3 2023 | 2023-09-30 | $1.5M | $412,948 | +38.73% |
| Q2 2023 | 2023-06-30 | $1.3M | $281,461 | +26.74% |
| Q1 2023 | 2023-03-31 | $1.3M | $375,855 | +41.87% |
| Q4 2022 | 2022-12-31 | $1.0M | $415,580 | +65.70% |
| Q3 2022 | 2022-09-30 | $1.1M | $429,406 | +67.43% |
| Q2 2022 | 2022-06-30 | $1.1M | $701,412 | +199.83% |
| Q1 2022 | 2022-03-31 | $897,650 | $715,425 | +392.61% |
| Q4 2021 | 2021-12-31 | $632,583 | — | — |
| Q3 2021 | 2021-09-30 | $636,806 | $326,341 | +105.11% |
| Q2 2021 | 2021-06-30 | $351,009 | $63,455 | +22.07% |
| Q1 2021 | 2021-03-31 | $182,225 | — | — |
| Q3 2020 | 2020-09-30 | $310,465 | — | — |
| Q2 2020 | 2020-06-30 | $287,554 | — | — |
Immuneering stock-based compensation trends
Over the last five fiscal years, Immuneering's stock-based compensation increased from $1.1M to $6.3M, a change of $5.2M. The latest reported quarter, Q2 2026, shows $1.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering source filings ↗